InMode (INMD) to Release Quarterly Earnings on Thursday

InMode (NASDAQ:INMD) is projected to post its Q2 2026 results before the market opens on Thursday, July 23rd. Analysts expect the company to announce earnings of $0.3327 per share and revenue of $93.0320 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 9:30 AM ET.

InMode (NASDAQ:INMD) last issued its earnings results on Wednesday, May 6th. The healthcare company reported $0.25 earnings per share for the quarter, missing the consensus estimate of $0.30 by ($0.05). InMode had a return on equity of 13.47% and a net margin of 23.27%.The company had revenue of $82.02 million for the quarter, compared to analyst estimates of $79.84 million. During the same quarter in the previous year, the company posted $0.31 earnings per share. The company’s quarterly revenue was up 5.3% compared to the same quarter last year.

InMode Trading Up 2.4%

Shares of InMode stock opened at $15.28 on Thursday. The company has a 50-day moving average of $14.05 and a two-hundred day moving average of $14.17. InMode has a 12-month low of $12.72 and a 12-month high of $16.74. The stock has a market cap of $878.29 million, a PE ratio of 11.24 and a beta of 1.91.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Quadrant Capital Group LLC boosted its stake in shares of InMode by 127.8% during the 4th quarter. Quadrant Capital Group LLC now owns 1,945 shares of the healthcare company’s stock worth $29,000 after purchasing an additional 1,091 shares during the last quarter. Advisory Services Network LLC purchased a new stake in shares of InMode during the third quarter worth about $37,000. Deutsche Bank AG raised its position in shares of InMode by 35.9% in the fourth quarter. Deutsche Bank AG now owns 3,927 shares of the healthcare company’s stock valued at $58,000 after buying an additional 1,037 shares during the last quarter. Parallel Advisors LLC raised its position in shares of InMode by 113.3% in the fourth quarter. Parallel Advisors LLC now owns 4,318 shares of the healthcare company’s stock valued at $63,000 after buying an additional 2,294 shares during the last quarter. Finally, Brooklyn Investment Group purchased a new position in shares of InMode during the fourth quarter valued at approximately $154,000. 68.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on INMD shares. Barclays set a $19.00 price target on InMode and gave the stock an “overweight” rating in a report on Thursday, May 7th. Robert W. Baird decreased their target price on InMode from $17.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, May 7th. One research analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, InMode has a consensus rating of “Hold” and a consensus price target of $16.00.

About InMode

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.